Skip to main content
SpringerLink
Log in

Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To determine long-term adherence to evidence-based secondary preventive combination pharmacotherapy in survivors of acute myocardial infarction (AMI) and to investigate the association between adherence to recommended therapy and all-cause mortality in claims data.

Methods

Prospective cohort study based on claims data of an 18.75 % random sample of all persons insured with the local statutory health insurance fund AOK Hesse. Study population included patients with hospital discharge diagnoses of AMI between 2001 and 2005 excluding those who died within the first 30 days after AMI or who had been hospitalised with an AMI in the previous 2 years. A total of 3,008 patients were followed up until death, cancellation of insurance, or the end of the study period on 31 December 2007, whichever came first (median follow-up: 4.2 years).

Results

Drug adherence to single drug groups as determined by proportion of days covered ≥80 % was 21.8 % for antiplatelet drugs, 9.4 % for beta-blockers, 45.6 % for ACE inhibitors or angiotensin II receptor blockers and 45.1 % for lipid-lowering drugs. A total of 924 (39.7 %) patients met our definition of guideline adherence: Drugs available from three of four relevant drug groups on the same day for at least 50 % of the observation time. Of the patients adhering to the guidelines, 17.3 % died and of the non-adherents, 32.4 % died. All-cause mortality was 28 % lower for guideline-adherent patients than for the non-adherent group (adjusted HR 0.72, 95 % CI 0.60–0.86).

Conclusions

In everyday practice, post AMI patients benefit from guideline-oriented treatment, but the percentage of adherent patients should be improved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K, together with members of the Task Force (1998) Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. J Hypertens 16:1407–1414

    Article  PubMed  CAS  Google Scholar 

  2. Deutsche Gesellschaft für Kardiologie-, Herz- und Kreislaufforschung (1998) Leitlinie koronare Herzkrankheit/Angina pectoris. Z Kardiol 87:907–911

    Google Scholar 

  3. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie—Herz- und Kreislaufforschung (DGK). Z Kardiol 92:501–521

    PubMed  CAS  Google Scholar 

  4. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al (2002) AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106:388–391

    Article  PubMed  Google Scholar 

  5. Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J et al (2002) Improving quality of care for acute myocardial infarction—the guidelines applied in practice (GAP) initiative. JAMA 287:1269–1276

    Article  PubMed  Google Scholar 

  6. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J et al (2007) MISSION! Optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 153:14.e1–14.e11

    Article  Google Scholar 

  7. Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R et al (1998) Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. Eur Heart J 19:74–79

    Article  PubMed  CAS  Google Scholar 

  8. Velasco JA (1999) After 4S, CARE and LIPID—Is evidence-based medicine being practised? Atherosclerosis 147(Suppl 1):S39–44

    Article  PubMed  CAS  Google Scholar 

  9. Brady AJ, Oliver MA, Pittard JB (2001) Secondary prevention in 24431 patients with coronary heart disease: survey in primary care. BMJ 322:1463

    Article  PubMed  CAS  Google Scholar 

  10. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462–467

    Article  PubMed  Google Scholar 

  11. Heidrich J, Liese AD, Kalic M, Winter-Enbergs A, Wellmann J, Roeder N et al (2002) Sekundärprävention der koronaren Herzkrankheit. Ergebnisse der EuroASPIRE I- und II-Studien in der Region Münster. Dtsch Med Wochenschr 127:667–672

    Article  PubMed  CAS  Google Scholar 

  12. Böger GI, Hoopmann M, Busse R, Budinger M, Welte T, Böger RH (2003) Arzneimittelverordnungen bei koronarer Herzkrankheit: Werden die Therapieempfehlungen beachtet?. Z Kardiol 92:466–475

    PubMed  Google Scholar 

  13. Küpper-Nybelen J, Rothenbacher D, Hahmann H, Wüsten B, Brenner H (2003) Veränderungen von Risikofaktoren nach stationärer Rehabilitation bei Patienten mit koronarer Herzkrankheit. Dtsch Med Wochenschr 128:1525–1530

    Article  PubMed  Google Scholar 

  14. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD et al (2004) Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 117:73–81

    Article  PubMed  Google Scholar 

  15. Austin PC, Tu JV, Ko DT, Alter DA (2008) Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ 179:895–900

    Article  PubMed  Google Scholar 

  16. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL (2009) Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 122:961.e7–961.e12

    Article  Google Scholar 

  17. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA (2004) Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109:745–749

    Article  PubMed  Google Scholar 

  18. Rogers AM, Ramanath VS, Grzybowski M, Riba AL, Jani SM, Mehta R et al (2007) The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology’s Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J 154:461–469

    Article  PubMed  Google Scholar 

  19. Gouya G, Reichardt B, Ohrenberger G, Wolzt M (2007) Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 22:145–149

    Article  PubMed  Google Scholar 

  20. Jackevicius CA, Li P, Tu JV (2008) Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117:1028–1036

    Article  PubMed  Google Scholar 

  21. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J (1990) Treatment adherence and risk of death after a myocardial infarction. Lancet 336:542–545

    Article  PubMed  CAS  Google Scholar 

  22. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS (2006) Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 166:1842–1847

    Article  PubMed  Google Scholar 

  23. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS (2006) Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord 6:48

    Article  PubMed  Google Scholar 

  24. Newby LK, Allen LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM (2006) Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113:203–212

    Article  PubMed  CAS  Google Scholar 

  25. Rasmussen JN, Chong A, Alter AD (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297:177–186

    Article  PubMed  CAS  Google Scholar 

  26. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155:772–779

    Article  PubMed  Google Scholar 

  27. Vokó Z, de Brouwer S, Lubsen J, Danchin N, Otterstad J-E, Dunselman PHJM, Kirwan B-A (2011) Long-term impact of secondary preventive treatments in patients with stable angina. Eur J Epidemiol. doi:10.1007/s10654-011-9558-5

  28. Ihle P, Köster I, Herholz H, Rambow-Bertram P, Schardt T, Schubert I (2005) Versichertenstichprobe AOK Hessen/KV Hessen – Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der gesetzlichen Krankenversicherung. Gesundheitswesen 67:638–645

    Article  PubMed  CAS  Google Scholar 

  29. Johnson ES, Mozaffari E (2002) Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care 8:S249–254

    PubMed  Google Scholar 

  30. Daly CA, De Stavola B, Sendon JLL, Tavazzi L, Boersma E, Clemens F et al (2006) Predicting prognosis in stable angina—results from the Euro Heart Survey of stable angina: prospective observational study. BMJ 332:262–267

    Article  PubMed  Google Scholar 

  31. Donner-Banzhoff N, Held K, Laufs U, Trappe H-J, Werdan K, Zerkowski H-R (2010) Nationale VersorgungsLeitlinie Chronische KHK. Langfassung. 2010; version 1.9, based on version from June 2006 http://www.versorgungsleitlinien.de/themen/khk/pdf/nvl_khk_lang.pdf. Accessed 5 Nov 2010

  32. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241–249

    Article  PubMed  Google Scholar 

  33. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55

    Article  Google Scholar 

  34. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S (2006) A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437–447

    Article  PubMed  Google Scholar 

  35. Briffa T, Hickling S, Knuiman M, Hobbs M, Hung J, Sanfilippo FM, Jamrozik P, Thompson PL (2009) Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ 338:b36

    Article  PubMed  Google Scholar 

  36. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC (2008) Improvement in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge. A 10-year trend analysis. J Am Coll Cardiol 51:1247–1254

    Article  PubMed  Google Scholar 

  37. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15

    Article  PubMed  Google Scholar 

  38. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166:348–354

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was funded by the Federal Ministry of Education and Research, the Federal Ministry of Health and the National Association of Statutory Health Insurance Funds, grant number: 01GL0505.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Herderstrasse 52, 50931, Cologne, Germany

    Jutta Kuepper-Nybelen, Sascha Abbas, Peter Ihle & Ingrid Schubert

  2. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, 50931, Cologne, Germany

    Martin Hellmich

  3. Clinics of Cologne, Clinic II for Internal Medicine, University of Cologne, 51058, Cologne, Germany

    Reinhard Griebenow

Authors
  1. Jutta Kuepper-Nybelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Hellmich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sascha Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Ihle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reinhard Griebenow
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ingrid Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingrid Schubert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuepper-Nybelen, J., Hellmich, M., Abbas, S. et al. Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data. Eur J Clin Pharmacol 68, 1451–1460 (2012). https://doi.org/10.1007/s00228-012-1274-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1274-x

Keywords

Search

Navigation